Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis : case report. / Holmstroem, Rikke Boedker; Dahl, Emilie Kristine; Helms, Morten; Nielsen, Henrik Vedel; Andersen, Janne Bayer; Bjerrum, Jacob Tveiten; Svane, Inge Marie; Ellebaek, Eva; Seidelin, Jakob Benedict.

I: BMJ Open Gastroenterology, Bind 9, Nr. 1, e000989, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Holmstroem, RB, Dahl, EK, Helms, M, Nielsen, HV, Andersen, JB, Bjerrum, JT, Svane, IM, Ellebaek, E & Seidelin, JB 2022, 'Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report', BMJ Open Gastroenterology, bind 9, nr. 1, e000989. https://doi.org/10.1136/bmjgast-2022-000989

APA

Holmstroem, R. B., Dahl, E. K., Helms, M., Nielsen, H. V., Andersen, J. B., Bjerrum, J. T., Svane, I. M., Ellebaek, E., & Seidelin, J. B. (2022). Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterology, 9(1), [e000989]. https://doi.org/10.1136/bmjgast-2022-000989

Vancouver

Holmstroem RB, Dahl EK, Helms M, Nielsen HV, Andersen JB, Bjerrum JT o.a. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterology. 2022;9(1). e000989. https://doi.org/10.1136/bmjgast-2022-000989

Author

Holmstroem, Rikke Boedker ; Dahl, Emilie Kristine ; Helms, Morten ; Nielsen, Henrik Vedel ; Andersen, Janne Bayer ; Bjerrum, Jacob Tveiten ; Svane, Inge Marie ; Ellebaek, Eva ; Seidelin, Jakob Benedict. / Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis : case report. I: BMJ Open Gastroenterology. 2022 ; Bind 9, Nr. 1.

Bibtex

@article{9a254421b5ef4cb483ad938ac9ad0619,
title = "Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report",
abstract = "BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.",
keywords = "Humans, Fecal Microbiota Transplantation/adverse effects, Antineoplastic Agents, Immunological/adverse effects, Enterocolitis/chemically induced, Colitis/therapy",
author = "Holmstroem, {Rikke Boedker} and Dahl, {Emilie Kristine} and Morten Helms and Nielsen, {Henrik Vedel} and Andersen, {Janne Bayer} and Bjerrum, {Jacob Tveiten} and Svane, {Inge Marie} and Eva Ellebaek and Seidelin, {Jakob Benedict}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2022",
doi = "10.1136/bmjgast-2022-000989",
language = "English",
volume = "9",
journal = "B M J Open Gastroenterology",
issn = "2054-4774",
publisher = "B M J Group",
number = "1",

}

RIS

TY - JOUR

T1 - Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis

T2 - case report

AU - Holmstroem, Rikke Boedker

AU - Dahl, Emilie Kristine

AU - Helms, Morten

AU - Nielsen, Henrik Vedel

AU - Andersen, Janne Bayer

AU - Bjerrum, Jacob Tveiten

AU - Svane, Inge Marie

AU - Ellebaek, Eva

AU - Seidelin, Jakob Benedict

N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.

AB - BACKGROUND: Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented.CASE PRESENTATION: We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib.CONCLUSION: This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.

KW - Humans

KW - Fecal Microbiota Transplantation/adverse effects

KW - Antineoplastic Agents, Immunological/adverse effects

KW - Enterocolitis/chemically induced

KW - Colitis/therapy

U2 - 10.1136/bmjgast-2022-000989

DO - 10.1136/bmjgast-2022-000989

M3 - Journal article

C2 - 36581371

VL - 9

JO - B M J Open Gastroenterology

JF - B M J Open Gastroenterology

SN - 2054-4774

IS - 1

M1 - e000989

ER -

ID: 333478308